Gammagard liquid 10%: Phase I/II data

Data from a U.S. Phase I/II trial in 11 patients showed that the average bioavailability of subcutaneous (SC) Gammagard Liquid 10% was 92% of the IV formulation. Patients received SC Gammagard monthly...